Next-generation cancer trial matching
For people with cancer, there are thousands of clinical trials of new treatments and approaches. It can be overwhelming trying to find the right ones.
Enter your patient's cancer information, and we will:
1. Find the trials that fit their cancer profile
2. Show you key information about each trial so you can decide if it's a good fit
Note: HealthScout is in early release and currently includes trials for advanced/metastatic non-small cell lung cancer and trials that accept solid tumors of any primary site. We are planning to add more cancer types soon! Click here to sign up for updates.
Or, have us guide you through the needed info (recommended for patients).
Guided InputHow It Works
1/Our AI translates your patient's info into a computer-readable format
"...had progression on carbo/taxol/Keytruda..."
- Had treatment regimen of:
- Carboplatin (drug class: cytotoxic chemotherapy)
- Paclitaxel (drug class: cytotoxic chemotherapy)
- Pembrolizumab (drug class: PD-1/PD-L1 inhibitor)
- Result of regimen: progression
2/This data is used to get a list of matching trials
Trial inclusion criterion:
Progression on regimen containing chemotherapy and PD-1/PD-L1 inhibitor
- Regimen must contain:
- ≥1 drug in class: cytotoxic chemotherapy
- ≥1 drug in class: PD-1/PD-L1 inhibitor
- Result of regimen must have been: progression
3/Learn about the matching trials and find the ones that are the best fit
Tags in the trials list help you zero in on the best trials:
Our analysis helps identify the most promising drugs and trials:
Zongertinib clinical results
Zongertinib has shown promising preliminary results in ongoing clinical trials. In the Beamion LUNG-1 trial (NCT04886804), a Phase Ia/Ib first-in-human study, zongertinib demonstrated high response rates, particularly among NSCLC patients.
The drug was well tolerated, with low rates of EGFR-mediated adverse events and no discontinuations due to adverse events recorded during the Phase Ib trial. Initial efficacy data from Phase Ib reflected a high objective response rate (ORR) of 74% and a disease control rate (DCR) of 91% [1].
[1] Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor, in patients with HER2-positive advanced NSCLC.
About Us
Who created HealthScout?
The HealthScout team is led by Michael Gensheimer MD, a radiation oncologist at Stanford University. Dr. Gensheimer noticed that many of his patients were interested in clinical trials but were struggling to find ones that were a good fit. This inspired him to create HealthScout.
Is the site secure?
Yes, user data is encrypted at all times and HealthScout lives on the secure Render.com platform. Also, you never need to enter any personal information like date of birth. We do ask for a name for each patient, but you can just use their initials or first name.
Is HealthScout free to use?
Yes it is. We do not share user data with any third parties.
